Daniel M Hartung - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Daniel M Hartung

Showing results (41-50 of 110) with videos related to

Pageof 11

Sort By:

JCO Oncology Practice|July 7, 2022

Medicare Part D Coverage Restrictions and Patient Cost-Sharing for Opioids Commonly Used for Cancer Pain, 2015-2021Yuhua Bao, Hao Zhang, Daniel M Hartung, et al.

The American Journal of Managed Care|July 12, 2024

Budget impact analysis of biosimilar natalizumab in the USEdward Li, Adrian Goh, Soni Gupta, et al.

Psychiatric Services (Washington, D.C.)|January 15, 2016

The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid ProgramHyunjee Kim, Daniel M Hartung, Reside L Jacob, et al.

Journal of Substance Use and Addiction Treatment|February 23, 2023

Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative dataDaniel M Hartung, Caitlin M McCracken, Thuan Nguyen, et al.

JAMA Health Forum|April 26, 2024

Changes in Buprenorphine Prescribing in Community Health CentersDaniel M Hartung, Robert W Voss, Steffani R Bailey, et al.

Health Affairs (Project Hope)|February 5, 2019

Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part DDaniel M Hartung, Kirbee A Johnston, Adriane Irwin, et al.

Obstetrics and Gynecology|May 29, 2019

Association of Pharmacist Prescription of Hormonal Contraception With Unintended Pregnancies and Medicaid CostsMaria I Rodriguez, Alyssa Hersh, Lorinda B Anderson, et al.

Neurology. Clinical Practice|September 6, 2021

Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis DrugsDaniel M Hartung, Kirbee A Johnston, Dennis N Bourdette, et al.

Pharmacoepidemiology and Drug Safety|September 17, 2020

A comparison of trends in opioid dispensing patterns between Medicaid pharmacy claims and prescription drug monitoring program dataSanae El Ibrahimi, Sara Hallvik, Kirbee Johnston, et al.

Journal of Substance Abuse Treatment|May 24, 2014

Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studiesDaniel M Hartung, Dennis McCarty, Rongwei Fu, et al.

Pageof 11

Search research articles

Showing results (41-50 of 110) with videos related to

Sort By:

Pageof 11

JCO Oncology Practice|July 7, 2022

Medicare Part D Coverage Restrictions and Patient Cost-Sharing for Opioids Commonly Used for Cancer Pain, 2015-2021Yuhua Bao, Hao Zhang, Daniel M Hartung, et al.

The American Journal of Managed Care|July 12, 2024

Budget impact analysis of biosimilar natalizumab in the USEdward Li, Adrian Goh, Soni Gupta, et al.

Psychiatric Services (Washington, D.C.)|January 15, 2016

The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid ProgramHyunjee Kim, Daniel M Hartung, Reside L Jacob, et al.

Journal of Substance Use and Addiction Treatment|February 23, 2023

Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative dataDaniel M Hartung, Caitlin M McCracken, Thuan Nguyen, et al.

JAMA Health Forum|April 26, 2024

Changes in Buprenorphine Prescribing in Community Health CentersDaniel M Hartung, Robert W Voss, Steffani R Bailey, et al.

Health Affairs (Project Hope)|February 5, 2019

Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part DDaniel M Hartung, Kirbee A Johnston, Adriane Irwin, et al.

Obstetrics and Gynecology|May 29, 2019

Association of Pharmacist Prescription of Hormonal Contraception With Unintended Pregnancies and Medicaid CostsMaria I Rodriguez, Alyssa Hersh, Lorinda B Anderson, et al.

Neurology. Clinical Practice|September 6, 2021

Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis DrugsDaniel M Hartung, Kirbee A Johnston, Dennis N Bourdette, et al.

Pharmacoepidemiology and Drug Safety|September 17, 2020

A comparison of trends in opioid dispensing patterns between Medicaid pharmacy claims and prescription drug monitoring program dataSanae El Ibrahimi, Sara Hallvik, Kirbee Johnston, et al.

Journal of Substance Abuse Treatment|May 24, 2014

Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studiesDaniel M Hartung, Dennis McCarty, Rongwei Fu, et al.

Pageof 11